drugset / Trial / NCT00741897

Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis

NCT00741897

Phase 4 Completed 264 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of Fexofenadine (Telfast®) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic rhinitis.

Timeline

Start
2002-03
Primary completion
2003-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexofenadine Unknown 30 mg